Autolus Therapeutics (NASDAQ:AUTL) Sets New 12-Month Low – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $2.85 and last traded at $2.86, with a volume of 131760 shares. The stock had previously closed at $2.95.

Analysts Set New Price Targets

Several analysts have recently issued reports on AUTL shares. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $7.00 to $7.60 in a research note on Monday. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Trading Up 1.3 %

The stock has a 50 day moving average price of $3.83 and a 200 day moving average price of $3.96. The company has a market cap of $754.37 million, a PE ratio of -2.35 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the previous year, the firm earned ($0.26) EPS. Equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new position in shares of Autolus Therapeutics in the 2nd quarter worth approximately $43,000. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics during the 3rd quarter worth approximately $51,000. Bayesian Capital Management LP bought a new stake in Autolus Therapeutics during the 1st quarter worth approximately $100,000. Daiwa Securities Group Inc. raised its stake in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after acquiring an additional 15,293 shares during the period. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in Autolus Therapeutics during the 1st quarter valued at approximately $108,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.